Trial Search Results

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Gilead Sciences

Stanford Investigator(s):

Intervention(s):

  • Drug: GS-5885
  • Drug: Tegobuvir
  • Drug: GS-9451
  • Drug: ribavirin tablet
  • Drug: GS-5885

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Adult subjects 18 to 70 years of age

   - Chronic HCV infection for at least 6 months prior to Baseline (Day 1)

   - Liver biopsy results (performed no more than 2 years prior to Screening) indicating
   the absence of cirrhosis

   - Monoinfection with HCV genotype 1a or 1b

   - HCV treatment-naïve

   - Body mass index (BMI) between 18 and 36 kg/m2

   - Creatinine clearance ≥ 50 mL/min

   - Subject agrees to use highly effective contraception methods if female of childbearing
   potential or sexually active male.

   - Screening laboratory values within defined thresholds

Exclusion Criteria:

   - Autoimmune disease

   - Decompensated liver disease or cirrhosis

   - Poorly controlled diabetes mellitus

   - Severe psychiatric illness

   - Severe chronic obstructive pulmonary disease (COPD)

   - Serological evidence of co-infection with human immunodeficiency virus (HIV),
   hepatitis B virus (HBV), or another HCV genotype

   - Suspicion of hepatocellular carcinoma or other malignancy (with exception of certain
   skin cancers)

   - History of hemoglobinopathy

   - Known retinal disease

   - Subjects who are immunosuppressed

   - Subjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine,
   heroin), methadone, or ongoing alcohol abuse

   - Subjects must have no history of clinically significant cardiac disease, including a
   family history of Long QT syndrome, and no relevant electrocardiogram (ECG)
   abnormalities at screening

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mindie H Nguyen, MD
650-498-7878
Not Recruiting